US EditionUS and UK agree zero-tariffs on pharmaceuticals
UK agrees to raise NHS drug prices by 25% and reform pricing rules in exchange for a zero tariff deal on pharmaceuticals exported to the US, protecting £5 billion in trade.
- On Monday , the United States government agreed to exempt U.K.-origin pharmaceuticals, ingredients, and medical technology from import taxes, securing a 0% tariff rate for at least 3 years.
- Amid investment pullbacks and tariff threats, major firms like AstraZeneca paused UK investments, intensifying pressure on ministers after months of talks following a spring bilateral trade pact and NHS disputes.
- Britain agreed to raise the net price it pays by 25%, while NICE's thresholds and rebate rules will be reformed, with rebate rates reducing toward 15%.
- Lawmakers and campaigners reacted sharply, with Helen Morgan saying `It cannot go ahead` and Diarmaid McDonald calling it `This is a betrayal of NHS patients`; UK media reported the NHS cost estimate at �3 billion, while 64% of the British public opposed higher NHS medicine prices.
- USTR officials said the deal will be a model for other nations, as ING analysts estimate Ireland could lose 8.7 billion annually, and the U.S. pledged not to challenge UK pharmaceutical pricing practices during Trump's term.
125 Articles
125 Articles
Trump Administration Locks In Zero Tariffs On UK Pharmaceuticals As NHS To Pay More For US Drugs - AstraZeneca (NASDAQ:AZN), GSK (NYSE:GSK)
The UK and the U.S. have reached a landmark agreement to eliminate tariffs on British pharmaceutical products being exported to America.
An agreement, concluded on Monday 1 December, avoids a salve of punitive tariffs on its pharmaceutical products in London. In return, the Starmer government has accepted a 25% price increase on new treatments.
UK Agrees to Pay More for US Medicines After Trade Negotiations
The UK’s National Health Service will pay 25 percent more for new, patented U.S. medicines under the terms of a new trade agreement between the two nations. The deal is the latest in a series of agreements in which the United States has leveraged tariffs to secure concessions on prescription drug prices. This is the first deal reached with a nation rather than with pharmaceutical manufacturers. In return for this concession, the United States wi…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
